Servier Pharmaceuticals
Manufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
200 Pier 4 Blvd, Boston, Massachusetts, ...Phone Number
(888) 788-1735Website
www.servier.usRevenue
$148.9 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
2
1
2
1
About Servier Pharmaceuticals
Servier Pharmaceuticals is a leader in oncology and is expanding its neurology business, focusing on addressing rare diseases and patient populations with unmet needs. The company is committed to delivering meaningful therapeutics through a robust research and development pipeline and partnerships. With 50 active programs in oncology and neurology, Servier aims to provide new therapeutic options for smaller patient populations. Their dedication to science and patient care drives their mission to improve the lives of those they serve.Explore more
Servier Pharmaceuticals Org Chart
SK
Senior Director, Clinical Science
AK
Senior Director, Clinical Development
FL
Director, Office Management
TT
Director, Regulatory Affairs & Quality Manage...
CG
Director, Clinical Science
WT
Director, Quality Assurance External Manufact...
DM
Associate Director, Clinical Biomarkers
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Servier Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Servier Pharmaceuticals had a recent Job posting/layoffs
Check if Servier Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if Servier Pharmaceuticals is spiking on competitors!
Servier Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Servier Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Servier Pharmaceuticals has new funding data
Earning: See what the market has to say on Servier Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Servier Pharmaceuticals
Recommended Actions
Reach out to Masked Content who joined Servier Pharmaceuticals as Masked Content
Find more new buyers
Compare Similar Companies to Servier Pharmaceuticals
Compare insights from companies similar to Servier Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$50.7M
51-200
Private
-
1999
AO
Aram OganesianVice President, Clinical Pharmacology & Nonclinical Development
Company Profile Activity
Activity Insights
Servier Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Servier Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Servier Pharmaceuticals.
Servier Pharmaceuticals Tech Stack
A closer look at the technologies used by Servier Pharmaceuticals
Most Recent Scoops
Hiring Plans
Servier Pharmaceuticals has more open roles in Medical & Health than it has had at any time in the past 12 months with an increased focus that include Medical Devices, and Medical Devices.
Hiring Plans
New Hire
Executive Move
Ami Kavi has recently joined the organization as Senior Director, Clinical Development. Previously, Kavi served as Director, Clinical Development (Solid Tumors) for BeOne Medicines.
Executive Moves, New Hire
Open Position
Open Position
Open Position
Servier Pharmaceuticals News & Media
Emiltatug Ledadotin (Emi-Le) Granted Breakthrough Therapy Designation by the U.S. FDA for Adenoid Cystic Carcinoma (ACC)
Emi-Le is a potentially innovative and differentiated antibody drug conjugate (ADC) directed against B7-H4, a well-characterized target in certain cancers including ACC Emi-Le is currently under clinical development in the U.S. for potential use in aggressive ACC and other cancers BOSTON,...David K. Lee: Servier Pharmaceuticals Finalizes Acquisition of Day One Biopharmaceuticals
David K. Lee: Servier Pharmaceuticals Finalizes Acquisition of Day One Biopharmaceuticals / cancer, David K. Lee, OncoDaily, Oncology, Pediatric cancer,Day One and Servier Complete Enrollment in Pivotal Phase 3 FIREFLY-2 Trial of Tovorafenib as a Front-Line Treatment for Pediatric Low-Grade Glioma (pLGG)
FIREFLY-2 is the largest study ever conducted in front-line pLGG Trial aims to extend OJEMDA's indication beyond relapsed/refractory setting to address significant unmet need; topline data expected by mid-2027 BOSTON, May 8, 2026 /PRNewswire/ -- Day One Biopharmaceuticals, Inc., now part...Servier's Clinical and Real-World Data at 2025 SNO Congress Showcase Leadership in IDH-Mutant Glioma
Presentations include seven company-sponsored abstracts and two investigator-initiated studies Oral presentation to highlight new analysis comparing volumetric and bidirectional assessments in patients with IDH-mutant Grade 2 glioma Safety data from a Phase 1b study evaluating the...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Servier Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Servier Pharmaceuticals is a leader in oncology and is expanding its neurology business, focusing on addressing rare diseases and patient populations with unmet needs. The company is committed to delivering meaningful therapeutics through a robust research and development pipeline and partnerships. With 50 active programs in oncology and neurology,... Read More
